Home
/
Mereo BioPharma Group plc
/
Financials
/
Quarterly
Mereo BioPharma Group plc — Quarterly Financials
Quarterly figures from SEC EDGAR XBRL filings (10-Q)
These figures are extracted from XBRL-tagged quarterly reports (10-Q) that Mereo BioPharma Group plc filed with the SEC. Values are as reported for each individual quarter (Q1, Q2, Q3, Q4) — not cumulative year-to-date. Negative figures indicate a loss.
Revenue — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
$0
Nov 10, 2025
Q2
2025
Jun 30, 2025
$500.0K
Aug 12, 2025
Q3
2025
Sep 30, 2024
$0
Nov 10, 2025
Q2
2025
Jun 30, 2024
$0
Aug 12, 2025
Q1
2024
Mar 31, 2024
$0
May 15, 2024
Q3
2024
Sep 30, 2023
$0
Nov 12, 2024
Q2
2024
Jun 30, 2023
$9.00M
Aug 13, 2024
Q1
2024
Mar 31, 2023
$0
May 15, 2024
Net Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($7.02M)
Nov 10, 2025
Q3
2025
Jun 30, 2025
($14.62M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($14.62M)
Aug 12, 2025
Q2
2025
Mar 31, 2025
($12.89M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($12.89M)
May 13, 2025
Q3
2025
Mar 31, 2025
($12.89M)
Nov 10, 2025
Q3
2025
Sep 30, 2024
($15.00M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($12.26M)
Aug 12, 2025
Q3
2025
Jun 30, 2024
($12.26M)
Nov 10, 2025
Q3
2025
Mar 31, 2024
($8.95M)
Nov 10, 2025
Q2
2025
Mar 31, 2024
($8.95M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($8.95M)
May 13, 2025
Q3
2024
Sep 30, 2023
($6.53M)
Nov 12, 2024
Q3
2024
Jun 30, 2023
($1.75M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($1.75M)
Aug 13, 2024
Q3
2024
Mar 31, 2023
($12.08M)
Nov 12, 2024
Q1
2024
Mar 31, 2023
($12.08M)
May 15, 2024
Q2
2024
Mar 31, 2023
($12.08M)
Aug 13, 2024
Operating Income — By Quarter
Quarter
Fiscal Year
Period End
Value
Filed
Q3
2025
Sep 30, 2025
($10.02M)
Nov 10, 2025
Q2
2025
Jun 30, 2025
($10.50M)
Aug 12, 2025
Q1
2025
Mar 31, 2025
($11.20M)
May 13, 2025
Q3
2025
Sep 30, 2024
($9.37M)
Nov 10, 2025
Q2
2025
Jun 30, 2024
($12.81M)
Aug 12, 2025
Q1
2025
Mar 31, 2024
($9.90M)
May 13, 2025
Q3
2024
Sep 30, 2023
($9.07M)
Nov 12, 2024
Q2
2024
Jun 30, 2023
($811.0K)
Aug 13, 2024
Q1
2024
Mar 31, 2023
($11.41M)
May 15, 2024